IFN-β Impairs Superoxide-Dependent Parasite Killing in Human Macrophages: Evidence for a Deleterious Role of SOD1 in Cutaneous Leishmaniasis

Journal of Immunology

Volumn 182, Issue 4, 2009, Pages 2525-2531

  Khouri, Ricardo ^a   Bafica, André ^b   Silva, Maria Da Purificação Pereira ^a   Noronha, Almerio ^a   Kolb, Jean Pierre ^d   Wietzerbin, Juana ^e   Barral, Aldina ^a,c   Barral Netto, Manoel ^a,c   Van Weyenbergh, Johan ^a,c  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c Institute for Investigation in Immunology INCT   (Brazil)

^d INSERM   (France)

^e INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; COPPER ZINC SUPEROXIDE DISMUTASE; SMALL INTERFERING RNA; SUPEROXIDE; NITRIC OXIDE; SUPEROXIDE DISMUTASE;

ANTIPROTOZOAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEISHMANIA; LEISHMANIA BRAZILIENSIS; LEISHMANIA MAJOR; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN LEISHMANIASIS; CELL CULTURE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; PARASITOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELLS, CULTURED; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-BETA; LEISHMANIASIS, CUTANEOUS; MACROPHAGES; NITRIC OXIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUPEROXIDE DISMUTASE; SUPEROXIDES;

EID: 61549139110     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0802860     Document Type: Article

References (50)

1. Desjeux, P. 2004. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 27: 305-318.
2. McMahon-Pratt, D., and J. Alexander. 2004. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniasis or the visceral disease? Immunol. Rev. 201: 206-224.
3. + T-cell subset differentiation. Res. Immunol. 142: 36-40.
4. Reiner, S. L., and R. M. Locksley. 1995. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13: 151-177.
5. Bogdan, C. 2008. Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example. Cell Microbiol. 10: 1221-1234.
6. Rocha, P. N., R. P. Almeida, O. Bacellar, A. R. de Jesus, D. C. Filho, A. C. Filho, A. Barral, R. L. Coffman, and E. M. Carvalho. 1999. Down-regulation of Th1 type of response in early human American cutaneous leishmaniasis. J. Infect. Dis. 180: 1731-1734.
7. Ribeiro-de-Jesus, A., R. P. Almeida, H. Lessa, O. Bacellar, and E. M. Carvalho. 1998. Cytokine profile and pathology in human leishmaniasis. Braz. J. Med. Biol. Res. 31: 143-148.
8. Carvalho, E. M., R. Badaró, S. G. Reed, T. C. Jones, and W. D. Johson, Jr. 1985. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J. Clin. Invest. 76: 2066-2069.
9. Badaro, R., E. Falcoff, F. S. Badaro, E. M. Carvalho, D. Pedral-Sampaio, A. Barral, J. S. Carvalho, M. Barral-Netto, M. Brandely, L. Silva, et al. 1990. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N. Engl. J. Med. 322: 16-21.
10. Diefenbach, A., H. Schindler, N. Donhauser, E. Lorenz, T. Laskay, J. MacMicking, M. Rollinghoff, I. Gresser, and C. Bogdan. 1998. Type 1 interferon (IFNα/β) and type 2 nitric oxide synthase regulate the innate immune response to a protozoan parasite. Immunity 8: 77-87.
11. Mattner, J., A. Wandersee-Steinhauser, A. Pahl, M. Rollinghoff, G. R. Majeau, P. S. Hochman, and C. Bogdan. 2004. Protection against progressive leishmaniasis by IFN-β. J. Immunol. 172: 7574-7582.
12. Passwell, J. H., R. Shor, and J. Shoham. 1986. The enhancing effect of interferon-β and -γ on the killing of Leishmania tropica major in human mononuclear phagocytes in vitro. J. Immunol. 136: 3062-3066.
13. Garotta, G., K. W. Talmadge, J. R. Pink, B. Dewald, and M. Baggiolini. 1986. Functional antagonism between type I and type II interferons on human macrophages. Biochem. Biophys. Res. Commun. 140: 948-954.
14. Van Weyenbergh, J., P. Lipinski, A. Abadie, D. Chabas, U. Blank, R. Liblau, and J. Wietzerbin. 1998. Antagonistic action of IFN-βand IFN-γon high affinity Fcγ receptor expression in healthy controls and multiple sclerosis patients. J. Immunol. 161: 1568-1574.
15. Ribeiro-Gomes, F. L., A. C. Otero, N. A. Gomes, M. C. A. Moniz-de-Souza, L. Cysne-Finkelstein, A. C. Arnholdt, V. L. Calich, S. G. Coutinho, M. F. Lopes, and G. A. DosReis. 2004. Macrophage interactions with neutrophils regulate Leishmania major infection. J. Immunol. 172: 4454-4462.
16. Saltzman, B. E. 1954. Colorimetric microdetermination of nitrogen dioxide in the atmosphere. Anal. Chem. 26: 1949-1955.
17. Zhao, H., N. Dugas, C. Mathiot, A. Delmer, B. Dugas, F. Sigaux, and J. P. Kolb. 1998. B-cell chronic lymphocytic leukemia cells express a functional inducible nitric oxide synthase displaying anti-apoptotic activity. Blood 92: 1031-1043.
18. Elstner, E. F., and A. Heupel. 1976. Inhibition of nitrite formation from hydroxylammoniumchloride: a simple assay for superoxide dismutase. Anal. Biochem. 70: 616-620.
19. Miranda, K. M., M. G. Espey, and D. A. Wink. 2001. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 5: 62-71.
20. Lipinski, P., and H. Retmanska. 1996. Horse spleen ferritin inhibits superoxide production by equine blood monocytes in vitro. Free Radic. Biol. Med. 20: 729-734.
21. Rothe, G., and G. Valet. 1990. Flow cytometric analysis of respiratory burst activity in phagocytes with hydroethidine and 2′,7′- dichlorofluorescein. J. Leukocyte Biol. 47: 440-448.
22. Mattner, J., H. Schindler, A. Diefenbach, M. Rollinghoff, I. Gresser, and C. Bogdan. 2000. Regulation of type 2 nitric oxide synthase by type 1 interferons in macrophages infected with Leishmania major. Eur. J. Immunol. 30: 2257-2267.
23. Gantt, K. R., T. L. Goldman, M. L. McCormick, M. A. Miller, S. M. Jeronimo, E. T. Nascimento, B. E. Britigan, and M. E. Wilson. 2001. Oxidative responses of human and murine macrophages during phagocytosis of Leishmania chagasi. J. Immunol. 167: 893-901.
24. Stetson, D. B., and R. Medzhitov. 2006. Type I IFN in host defense. Immunity 25: 373-381.
25. Bogdan, C., J. Mattner, and U. Schleicher. 2004. The role of type I interferons in non-viral infections. Immunol. Rev. 202: 33-48.
26. Trau, H., M. Schewach-Millet, J. Shoham, T. Doerner, R. Shor, and J. H. Passwell. 1987. Topical application of human fibroblast interferon (IFN) in cutaneous leishmaniasis. Isr. J. Med. Sci. 23: 1125-1127.
27. Ghosh, S., S. Goswami, and S. Adhya. 2003. Role of superoxide dismutase in survival of Leishmania within the macrophage. Biochem. J. 369: 447-452.
28. Plewes, K. A., S. D. Barr, and L. Gedamu. 2003. Iron superoxide dismutases targeted to the glycosomes of Leishmania chagasi are important for survival. Infect. Immun. 7: 5910-5920.
29. Barral, A., J. M. Costa, A. L. Bittencourt, M. Barral-Netto, and E. M. Carvalho. 1995. Polar and subpolar diffuse cutaneous leishmaniasis in Brazil: clinical and immunopathologic aspects. Int. J. Dermatol. 34: 474-479.
30. Lemos de Souza, V., J. Ascencao Souza, T. M. Correia Silva, P. Sampaio Tavares Veras, and L. A. Rodrigues de-Freitas. 2000. Different Leishmania species determine distinct profiles of immune and histopathological responses in CBA mice. Microbes Infect. 2: 1807-1815.
31. Gomes, I. N., A. F. Calabrich, S. Tavares Rda, J. Wietzerbin, L. A. de Freitas, and P. S. Veras. 2003. Differential properties of CBA/J mononuclear phagocytes recovered from an inflammatory site probed with two different species of Leishmania. Microbes Infect. 5: 251-260.
32. Mukbel, R. M., C. Patten, Jr., K. Gibson, M. Ghosh, C. Petersen, and D. E. Jones. 2007. Macrophage killing of Leishmania amazonensis amastigotes requires both nitric oxide and superoxide. Am. J. Trop. Med. Hyg. 76: 669-675.
33. Thoma-Uszynski, S., S. Stenger, O. Takeuchi, M. T. Ochoa, M. Engele, P. A. Sieling, P. F. Barnes, M. Rollinghoff, P. L. Bolcskei, M. Wagner, et al. 2001. Induction of direct antimicrobial activity through mammalian Toll-like receptors. Science 291: 1544-1547.
34. Bouchonnet, F., N. Boechat, M. Bonay, and A. J. Hance. 2002. Alpha/beta interferon impairs the ability of human macrophages to control growth of Mycobacterium bovis BCG. Infect. Immun. 70: 3020-3025.
35. Barral, A., M. Teixeira, P. Reis, V. Vinhas, J. Costa, H. Lessa, A. L. Bittencourt, S. Reed, E. M. Carvalho, and M. Barral-Netto. 1995. Transforming growth factor β in human cutaneous leishmaniasis. Am. J. Pathol. 147: 947-954.
36. Gantt, K. R., S. Schultz-Cherry, N. Rodriguez, S. M. Jeronimo, E. T. Nascimento, T. L. Goldman, T. J. Recker, M. A. Miller, and M. E. Wilson. 2003. Activation of TGF-β by Leishmania chagasi: importance for parasite survival in macrophages. J. Immunol. 170: 2613-2620.
37. Chang, H. K., C. Thalhofer, B. A. Duerkop, J. S. Mehling, S. Verma, K. J. Gollob, R. Almeida, and M. E. Wilson. 2007. Oxidant generation by single infected monocytes after short-term fluorescence labeling of a protozoan parasite. Infect. Immun. 75: 1017-1024.
38. Lu, H. T., J. L. Riley, G. T. Babcock, M. Huston, G. R. Stark, J. M. Boss, and R. M. Ransohoff. 1995. Interferon (IFN) beta acts downstream of IFN-gammainduced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNAbinding protein, ISGF3-gamma. J. Exp. Med. 182: 1517-1525.
39. Testa, U., L. Conti, N. M. Sposi, B. Varano, E. Tritarelli, W. Malorni, P. Samoggia, G. Rainaldi, C. Peschle, F. Belardelli, et al. 1995. IFN-beta selectively down-regulates transferrin receptor expression in human peripheral blood macrophages by a post-translational mechanism. J. Immunol. 155: 427-435.
40. Murray, H. W., A. Szuro-Sudol, D. Wellner, A. J. Oca, A. M. Granger, D. M. Libby, C. D. Rothermel, and B. Y. Rubin. 1989. Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of gamma interferon-stimulated human macrophages. Infect. Immun. 57: 845-849.
41. Pesce, A., E. Rosenthal, H. Vinti, B. Taillan, G. Garnier, P. Dujardin, and J. P. Cassuto. 1993. Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1 infected patients. Lancet 341: 1597.
42. Toren, A., A. Ackerstein, D. Gazit, R. Or, D. Raveh, U. Kupolovicz, D. Engelhard, and A. Nagler. 1996. Oral tuberculosis following autologous bone marrow transplantation for Hodgkin's disease with interleukin-2 and alpha-interferon immunotherapy. Bone Marrow Transplant. 18: 209-210.
43. Der, S. D., A. Zhou, B. R. Williams, and R. H. Silverman. 1998. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc. Natl. Acad. Sci. USA 95: 15623-15628.
44. Rani, M. R., J. Shrock, S. Appachi, R. A. Rudick, B. R. Williams, and R. M. Ransohoff. 2007. Novel interferon-β-induced gene expression in peripheral blood cells. J. Leukocyte Biol. 82: 1353-1360.
45. Satoh, J., Y. Nanri, H. Tabunoki, and T. Yamamura. 2006. Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNβ-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNβ-related adverse effects in multiple sclerosis. BMC Neurol. 6: 18.
46. Singh, M. K., T. F. Scott, W. A. LaFramboise, F. Z. Hu, J. C. Post, and G. D. Ehrlich. 2007. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing β-interferon therapy. J. Neurol. Sci. 258: 52-59.
47. Van Weyenbergh, J., J. Wietzerbin, D. Rouillard, M. Barral-Netto, and R. Liblau. 2001. Treatment of multiple sclerosis patients with interferon-β primes monocyte-derived macrophages for apoptotic cell death. J. Leukocyte Biol. 70: 745-748.
48. Prinz, M., H. Schmidt, A. Mildner, K. P. Knobeloch, U. K. Hanisch, J. Raasch, D. Merkler, C. Detje, I. Gutcher, J. Mages, et al. 2008. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 28: 675-686.
49. Tourbah, A., and O. Lyon-Caen. 2007. Interferons in multiple sclerosis: ten years' experience. Biochimie 89: 899-902.
50. Oh, U., Y. Yamano, C. A. Mora, J. Ohayon, F. Bagnato, J. A. Butman, J. Dambrosia, T. P. Leist, H. McFarland, and S. Jacobson. 2005. Interferon-β1a therapy in human T-lymphotropic virus type I-associated neurologic disease. Ann. Neurol. 57: 526-534.